MedTrace Logo

Correlation Between Platelet Function Analyzer-100 Testing and Bleeding Events After Percutaneous Kidney Biopsy

NCT03762707 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2019-06-18

No results posted yet for this study

Summary

Kidney biopsy represents the criterion standard to obtain information on diagnosis and prognosis of renal dysfunctions . Many patients with kidney disease have a predisposition to bleed, especially when they undergo an invasive procedure such as renal biopsy. The predominant factor is abnormal platelet function. Therefore, the aim of this study is to evaluate whether the platelet function analyzer (PFA-100), a very reliable test to investigate primary hemostasis, can be useful in predicting the risk of bleeding complications in patients undergoing renal biopsy.

Conditions

Sponsors & Collaborators

  • Prof. Carlo Manno

    collaborator UNKNOWN

  • Dott. Francesco Pesce

    collaborator UNKNOWN

  • Dott. Michele Rossini

    collaborator UNKNOWN

  • Dott. Vincenzo Di Leo

    collaborator UNKNOWN

  • Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-13
Primary Completion
2019-07-01
Completion
2019-09-01

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03762707 on ClinicalTrials.gov